Structure-Based Design of Nonpeptidic HIV Protease Inhibitors: The Sulfonamide-Substituted Cyclooctylpyranones
作者:Harvey I. Skulnick、Paul D. Johnson、Paul A. Aristoff、Jeanette K. Morris、Kristine D. Lovasz、W. Jeffrey Howe、Keith D. Watenpaugh、Musiri N. Janakiraman、David J. Anderson、Robert J. Reischer、Theresa M. Schwartz、Lee S. Banitt、Paul K. Tomich、Janet C. Lynn、Miao-Miao Horng、Kong-Teck Chong、Roger R. Hinshaw、Lester A. Dolak、Eric P. Seest、Francis J. Schwende、Bob D. Rush、Gina M. Howard、Lisa N. Toth、Karen R. Wilkinson、Thomas J. Kakuk、Carol W. Johnson、Serena L. Cole、Renee M. Zaya、Gail L. Zipp、Peggy L. Possert、Robert J. Dalga、Wei-Zhu Zhong、Marta G. Williams、Karen R. Romines
DOI:10.1021/jm960441m
日期:1997.3.1
substituents (e.g. 2c) were identified as potent, nonpeptidic HIV protease inhibitors, but these compounds lacked significant antiviral activity in cell culture. Substitution of a sulfonamide group at the meta position, however, produces compounds with excellent HIV protease binding affinity and antiviral activity. Guided by an iterative structure-based drug design process, we have prepared and evaluated a
最近,具有间甲酰胺取代基(例如2c)的环辛基吡喃酮衍生物被确定为有效的非肽类HIV蛋白酶抑制剂,但这些化合物在细胞培养中缺乏显着的抗病毒活性。然而,在间位取代磺酰胺基团会产生具有出色的HIV蛋白酶结合亲和力和抗病毒活性的化合物。在基于迭代结构的药物设计过程的指导下,我们已经准备并评估了许多此类衍生物,这些衍生物可通过七步合成轻松获得。进一步评估了一些最有效的化合物在大鼠和狗中的药代动力学和毒性等特性。通过这项工作,对氰基苯基磺酰胺衍生物35k成为有前途的抑制剂,被选择用于进一步开发,并进入了I期临床试验。